Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.
about
A review of human drug self-administration procedures.The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitabilityAbuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.A practical and ethical solution to the opioid scheduling conundrum.Current topics in opioid therapy for pain management: addressing the problem of abuse.Kitchen chemistry: A scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions.Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.Development of an Abuse- and Alcohol-Resistant Formulation Based on Hot-Melt Extrusion and Film Coating.The role of abuse-deterrent formulations in countering opioid misuse and abuse.Opioid abuse-deterrent strategies: role of clinicians in acute pain management.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets.Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.Crush resistance and insufflation potential of poly(ethylene oxide)-based abuse deterrent formulations.
P2860
Q33841805-293D489E-8F05-47C8-80A8-02B05FDA3C95Q35209803-CBB639E1-F162-465B-90E2-454630196194Q36549049-ADDA83E4-F22D-49AF-AE80-5E7A86804518Q36878938-99A37877-83B3-4236-BAD6-951141617E9AQ37390980-364C800C-71BD-4E98-BD09-B5C4F82E7758Q38112360-49FCF97C-934E-43E7-BE22-E6305A347A47Q38195230-516B1F4F-960C-46E0-B62F-50D8679790E1Q38241632-09DE83A4-7551-45FC-8FFD-461E9621093EQ38619508-E8480932-EB98-4B55-8CB0-B1EA6AFBB2BEQ38643510-127F4CDE-A8B4-4A15-A2D9-FFF575658530Q38657470-567C342E-ACE9-4C68-952F-E3A6752F8BF3Q38683620-FB6D4A1C-F8A5-4C71-A25B-59AE2B1F4EC4Q38707436-52DC736B-B581-459D-970D-91712C494CB9Q44184161-52234E32-24F3-430A-AB62-28242ED37AF3Q44340245-8D02BE8B-61F1-429D-9282-0EC5AB8C3E5EQ44342495-31EF71FF-EA54-4AF5-A874-729AC06E2CEBQ44345212-700FAE9B-CE4A-480E-B5AA-075B9D1C2870Q53638999-B748CD34-8AEE-4788-A76E-F1126E11C4EEQ53777935-44E04F77-9355-4677-8CD9-CE524668D0FE
P2860
Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Assessment of a formulation de ...... n prescription opioid abusers.
@en
type
label
Assessment of a formulation de ...... n prescription opioid abusers.
@en
prefLabel
Assessment of a formulation de ...... n prescription opioid abusers.
@en
P2093
P2860
P1476
Assessment of a formulation de ...... n prescription opioid abusers.
@en
P2093
Irma H Benedek
Jeanne M Manubay
Jermaine D Jones
Judy B Ashworth
Sandra D Comer
Suzanne K Vosburg
P2860
P304
P356
10.1016/J.DRUGALCDEP.2012.05.013
P577
2012-06-20T00:00:00Z